Read more

October 26, 2022
1 min read
Save

Top in endocrinology: Menopausal hormone therapy; managing hyperglycemia

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

A study of women with menopause aged 45 to 60 years found that menopausal hormone therapy may reduce the odds of developing adhesive capsulitis.

“We know that estrogen plays an important role in the musculoskeletal system; stimulating new bone formation, promoting muscle growth and repair, maintaining connective tissue integrity and reducing inflammation,” Anne C. Ford, MD, NCMP, an associate professor of obstetrics and gynecology at Duke University Medical Center, told Healio. “Our study draws attention to estrogen’s potential benefit apart from the FDA-approved indications — vasomotor symptoms, bone protection and vulvovaginal atrophy.”

hormone therapy with syringe
A study of women with menopause aged 45 to 60 years found that menopausal hormone therapy may reduce the odds of developing adhesive capsulitis. Source: Adobe Stock

A review of the study was the top story in endocrinology last week.

Another top story was about an updated consensus statement on the management of hyperglycemia among adults with type 2 diabetes. It was recently published in Diabetes Care.

Read these and more top stories in endocrinology below:

Menopausal hormone therapy may protect against adhesive capsulitis

Women who did not receive menopausal hormone therapy had greater odds of developing adhesive capsulitis compared with those on hormone therapy, according to preliminary study results presented at the North American Menopause Society annual meeting. Read more.

ADA, EASD update consensus report on managing hyperglycemia in type 2 diabetes

The American Diabetes Association and the European Association for the Study of Diabetes released an updated consensus statement on the management of hyperglycemia among adults with type 2 diabetes. Read more.

‘Disrupt’ therapeutic inertia with precision medicine to achieve diabetes remission

The concepts of precision diabetes medicine, including individualized therapy, carefully tracked progress and a team approach, can break down therapeutic inertia barriers and help patients achieve remission, according to a speaker. Read more.

Continuous glucose monitoring use increasing among young people, linked to lower HbA1c

Use of continuous glucose monitoring among children and young adults with type 1 diabetes nearly doubled from 2017 to 2020 in the U.S. from 25% to 49% and was associated with lower HbA1c for users vs. non-users, according to registry data. Read more.

Low BMD z scores common among gender-affirming youths prior to treatment

About 30% of a cohort of gender-diverse youths had low whole-body bone mineral density z scores prior to initiation of puberty blockers or gender-affirming hormones, according to findings published in Transgender Health. Read more.